Safety and Efficacy of Endovascular Fiducial Marker Insertion for CyberKnife Stereotactic Radiation Therapy Planning in Early-Stage Lung Cancer

Mongeon, M.; Thibault, Florence; Chartrand-Lefèbvre, Carl; Gorgos, Andrei; Soulez, Gilles; Filion, Édith; Thérasse, Éric

doi:10.1016/j.jvir.2017.05.010

Cited by 9 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We reserved the use of coils for frail patients whose peripheral tumors preclude the use of the Xspine ® technique. As expected, we observed no complications (21,22). The number of fiducials implanted did not appear to be of significant relevance to the probability of local control.…”

Section: Endovascular Coilssupporting

confidence: 82%

Cyberknife® stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months

et al. 2018

View full text Add to dashboard Cite

The best results were obtained with small lesions. With Synchrony, the distance of the target relative to the fiducial markers should be less than 50 mm. Gold seeds are recommended, although coils may be used instead of gold seeds. The number of fiducial markers did not have a significant impact on the probability of local control. With an appropriate tracking method, stereotactic radiotherapy is an efficient treatment for stage I lung cancer and lung oligometastases.

show abstract

Section: Endovascular Coilssupporting

confidence: 82%

Cyberknife® stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Smaller case series have examined endobronchial and endovascular FM placement as alternatives to percutaneous FM placement [ 25 , 29 , 30 ]. Mongeon et al [ 25 ] compared endovascular FM placement with percutaneous placement and reported no complications associated with endovascular marker insertion. In the percutaneous group, 52.6% of patients had a mild pneumothorax, and 11.4% had a pneumothorax that required chest tube drainage.…”

Section: Discussionmentioning

confidence: 99%

“…However, minor and major complications due to marker implantation and FM migration have been reported [ 12 , 20 , 21 , 22 , 23 , 24 , 25 ]. FM migration and inter-fiducial geometric changes can lead to inaccuracies or treatment interruptions during RRS [ 26 ].…”

Section: Introductionmentioning

confidence: 99%

Risks and Benefits of Fiducial Marker Placement in Tumor Lesions for Robotic Radiosurgery: Technical Outcomes of 357 Implantations

Kord

Kluge

Kufeld

et al. 2021

Cancers

View full text Add to dashboard Cite

Fiducial markers (FM) inserted into tumors increase the precision of irradiation during robotic radiosurgery (RRS). This retrospective study evaluated the clinical complications, marker migration, and motion amplitude of FM implantations by analyzing 288 cancer patients (58% men; 63.1 ± 13.0 years) who underwent 357 FM implantations prior to RRS with CyberKnife, between 2011 and 2019. Complications were classified according to the Society of Interventional Radiology (SIR) guidelines. The radial motion amplitude was calculated for tumors that moved with respiration. A total of 725 gold FM was inserted. SIR-rated complications occurred in 17.9% of all procedures. Most complications (32.0%, 62/194 implantations) were observed in Synchrony®-tracked lesions affected by respiratory motion, particularly in pulmonary lesions (46.9% 52/111 implantations). Concurrent biopsy sampling was associated with a higher complication rate (p = 0.001). FM migration occurred in 3.6% after CT-guided and clinical FM implantations. The largest motion amplitudes were observed in hepatic (20.5 ± 11.0 mm) and lower lung lobe (15.4 ± 10.5 mm) lesions. This study increases the awareness of the risks of FM placement, especially in thoracic lesions affected by respiratory motion. Considering the maximum motion amplitude, FM placement remains essential in hepatic and lower lung lobe lesions located >100.0 mm from the spine.

show abstract

“…Radiation therapy has been widely used for the treatment of tumors, 16,17 and stereotactic ablative body radiosurgery, yttrium 90 radioembolization, and iodine-125 seed implantation have all shown encouraging results for the treatment of some solid tumors. 12,18,19 Iodine-125 seed implantation has been used to treat HCC with encouraging efficacy.…”

Section: Discussionmentioning

confidence: 99%

Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study

et al. 2020

View full text Add to dashboard Cite

Objective To determine if iodine-125 seed implantation improved the efficacy of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) (≤5 cm). Methods We retrospectively reviewed the medical records of 83 consecutive patients with HCC (≤5 cm) who underwent TACE or TACE–iodine-125 from January 2014 to July 2017. The primary endpoint was progression-free survival (PFS). The secondary endpoints were overall survival (OS) and objective response rate (ORR) at 3 months after the first TACE treatment. PFS and OS were calculated using the Kaplan–Meier method and compared using log-rank tests. Independent risk factors for PFS and OS were analyzed using a Cox proportional hazards model. Results Thirty-five patients received TACE–iodine-125 and 48 received TACE alone. The median OS and PFS were both significantly longer in the TACE–iodine-125 compared with the TACE-alone group (42 vs 23 months and 16 vs 8 months, respectively). The ORR was significantly higher in the TACE–iodine-125 compared with the TACE-alone group. There was no significant difference in adverse events, apart from decreased white cell count, between the two groups. Conclusion TACE–iodine-125 might be an effective and safe alternative treatment for patients with HCC (≤5 cm).

show abstract

Safety and Efficacy of Endovascular Fiducial Marker Insertion for CyberKnife Stereotactic Radiation Therapy Planning in Early-Stage Lung Cancer

Cited by 9 publications

References 18 publications

Cyberknife® stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months

Cyberknife® stereotactic radiation therapy for stage I lung cancer and pulmonary metastases: evaluation of local control at 24 months

Risks and Benefits of Fiducial Marker Placement in Tumor Lesions for Robotic Radiosurgery: Technical Outcomes of 357 Implantations

Transarterial chemoembolization combined with iodine-125 seed implantation for patients with hepatocellular carcinoma: a retrospective controlled study

Contact Info

Product

Resources

About